Preview

Атеротромбоз

Расширенный поиск

К ВОПРОСУ О БЕЗОПАСНОСТИ ПРЯМЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ: РЕЗУЛЬТАТЫ СОПОСТАВЛЕНИЯ АПИКСАБАНА И ВАРФАРИНА

https://doi.org/10.21518/2307-1109-2018-2-54-67

Полный текст:

Аннотация

В обзоре анализируются данные о безопасности применения апиксабана для профилактики тромбоэмболических осложнений у больных с неклапанной фибрилляцией предсердий и венозными тромбоэмболическими осложнениями, полученные в рамках рандомизированных контролируемых исследований.

Об авторе

И. С. Явелов
Федеральное государственное бюджетное учреждение «Национальный медицинский исследовательский центр профилактической медицины» Министерства здравоохранения Российской Федерации
Россия

Явелов Игорь Семенович – д.м.н., ведущий научный сотрудник отдела клинической кардиологии и молекулярной генетики

тел.: (495) 623–86–36

101990, г. Москва, Петроверигский переулок, д. 10, стр. 3.



Список литературы

1. Kirchhof P., BenusSi S., Kotecha D., et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The task Force for the management of atrial fibrillation of the european society of Cardiology (ESC). Developed with the special contribution of the european Heart Rhythm Association (EHRA) of the ESC. endorsed by the european stroke organisation (ESO). Eur Heart J. 2016; 50: e1-e88.

2. Steffel J., Verhamme P., Potpara T.S., et al. The 2018 european Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2018; 39: 1330-1393.

3. Konstantinides S., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. the task Force for the Diagnosis and Management of Acute Pulmonary embolism of the european society of Cardiology (ESC). endorsed by the european Respiratory society (ERS). Eur Heart J. 2014; 35: 3033-3069.

4. Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE Disease. Chest Guideline and expert Panel Report. Chest. 2016; 149: 315-352.

5. Hsu J.C., Maddox T.M., Kennedy K.F., et al. Oral Anticoagulant therapy Prescription in Patients with Atrial Fibrillation Across the spectrum of stroke Risk Insights from the NCDR PINNACLE Registry. JAMA Cardiol. 2016; 1: 55-62.

6. Степина Е.В., Лукьянов М.М., Бичурина М.А., Белова Е.Н., Кудряшов Е.В., Юзьков Ю.В., Бойцов С.А. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью на госпитальном и амбулаторном этапах лечения по данным регистра РЕКВАЗА-КЛИНИКА. Рациональная фармакотерапия в кардиологии. 2017; 13(2):146-154. [Stepina E.V., Lukyanov M.M., Bichurina M.A., Belova E.N., Kudryashov E.V., Yuzkov Yu.V., Boytsov S.A. Therapy with oral anticoagulants in patients with atrial fibrillation in combination with arterial hypertension, ischemic heart disease, chronic heart failure in the hospital and outpatient stages of treatment according to the REQUESIS CLINIC register. Rational pharmacotherapy in cardiology. 2017; 13 (2): 146-154.]

7. Бойцов С.А., Марцевич С.Ю., Кутишенко Н.П., Лукьянов М.М., и соавт. Исследование «РЕГИстр больных, перенесших Острое Нарушение мозгового кровообращения (РЕГИОН)». Часть 1. Госпитальный проспективный регистр больных, перенесших острое нарушение мозгового кровообращения (по результатам пилотного этапа исследования). Рациональная фармакотерапия в кардиологии. 2016; 12(6): 645-653. [Boytsov S.A., Martsevich S.Yu., Kutishenko N.P., Lukyanov M.M., et al. The study “Register of patients who had Acute Cerebrovascular disease (REGION)”. Part 1. Hospital prospective register of patients who had acute cerebral circulation (according to the results of the pilot phase of the study). Rational pharmacotherapy in cardiology. 2016; 12 (6): 645-653.]

8. Haas S., Ten Cate H., Accetta G., et al.; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. PLoS One. 2016; 11: e0164076.

9. Гайсенок О.В., Леонов А.С. Применение пероральных антикоагулянтов у пациентов с фибрилляцией предсердий: данные когортного исследования. Рациональная фармакотерапия в кардиологии. 2016;12: 376-379. [Gaisenok O.V., Leonov A.S. The use of oral anticoagulants in patients with atrial fibrillation: cohort data. rational pharmacotherapy in cardiology. 2016; 12: 376-379.]

10. Granger C.B., Alexander J.H., McMurray J.J., et al., for the ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365: 981-992.

11. Hylek e.M., Held C., Alexander J.H., et al. Major Bleeding in Patients with Atrial Fibrillation Receiving Apixaban or Warfarin in the ARISTOTLE trial: Predictors, Characteristics, and Clinical outcomes. JACC. 2014; 63: 2141-2147.

12. Lopes R.D., Al-Khatib S.M., Wallentin L., et al. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomized controlled trial. Lancet. 2012; 380: 1749-1758.

13. Hohnloser S.H., Hijazi Z., Thomas L., et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012; 33: 2821-2830.

14. Wallentin L., Lopes R.D., Hanna M., et al. Efficacy and safety of apixaban compared with warfarin in different levels of predicted INR control for stroke prevention in atrial fibrillation. Circulation. 2013: 127: 2166-2176.

15. Halvorsen S., Atar D., Yang H., et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014; 35:1864-1872.

16. Alexander J.H., Andersson U., Lopes R.D., et al.; For the Apixaban for Reduction of stroke and other thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5mg twice Daily and Clinical outcomes in Patients With Atrial Fibrillation and Advanced Age, LowBodyWeight, or High Creatinine. A secondary Analysis of a Randomized Clinical trial. JAMA Cardiol. 2016; 1: 673-681.

17. Rao M.P., Vinereanu D., Wojdyla D.M., et al. Clinical outcomes and History of Fall in Patients with Atrial Fibrillation treated with oral Anticoagulation: Insights from the ARISTOTLE trial. Am J Med. 2018; 131: 269-275.

18. De Caterina R., Andersson U., Alexander J.H., et al.; ARISTOTLE Investigators. History of bleeding and outcomes with apixaban versus warfarin in patients with atrial fibrillation in the Apixaban for Reduction in stroke and other thromboembolic events in Atrial Fibrillation trial. Am Heart J. 2016: 175-183.

19. Lanas F., Xavier D., Husted s., et al. Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial. BMJ. 2016; 353: i2868.

20. Flaker G., Lopes R.D., Hylek e., et al.; ARISTOTLE Committees and Investigators. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. JACC. 2014; 64: 1541-1550.

21. Alexander J.H., Lopes R.D., Thomas L., et al. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2014; 35: 224-232.

22. Bahit M.C., Lopes R.D., Wojdyla D.M., et al. Apixaban in patients with atrial fibrillation and prior coronary artery disease: insights from the ARISTOTLE trial. Int J Cardiol. 2013; 170: 215-220.

23. Hu P.T., Lopes R.D., Stevens S.R., et al. Efficacy and safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE trial. J Am Heart Assoc. 2017 Jan 17;6(1). pii: e004699. doi:10.1161/JAHA.116.004699.

24. Agnelli G., Buller H.R., Cohen A., et al., For the AMPLIFY Investigators. oral Apixaban for the treatment of Acute Venous thromboembolism. N Engl J Med. 2013; 369: 799-808.

25. Raskob G.E., Gallus A.S., Sanders P., et al. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial. Thromb Haemost. 2016; 115: 809-816.

26. Sharma M., Cornelius V.R., Patel J.P., et al. Efficacy and Harms of Direct oral Anticoagulants in the elderly for stroke Prevention in Atrial Fibrillation and secondary Prevention of Venous thromboembolism: systematic Review and Meta-Analysis. Circulation. 2015; 132: 194-204.

27. Li X., DeitelzweIg S., Keshishian A., et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “realworld” clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost. 2017. doi:10.1160/tH17-01-0068.


Для цитирования:


Явелов И.С. К ВОПРОСУ О БЕЗОПАСНОСТИ ПРЯМЫХ ПЕРОРАЛЬНЫХ АНТИКОАГУЛЯНТОВ: РЕЗУЛЬТАТЫ СОПОСТАВЛЕНИЯ АПИКСАБАНА И ВАРФАРИНА. Атеротромбоз. 2018;(2):54-67. https://doi.org/10.21518/2307-1109-2018-2-54-67

For citation:


Yavelov I.S. CONSIDERING QUESTION OF SAFETY OF DIRECT ORAL ANTICOAGULANTS: THE RESULTS OF THE COMPARISON OF APIXABAN AND WARFARIN. Atherothrombosis Journal. 2018;(2):54-67. (In Russ.) https://doi.org/10.21518/2307-1109-2018-2-54-67

Просмотров: 288


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)